Database to promote the marketing of BioTime's research products ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...

This East Bay molecular diagnostics company shunned the traditional IPO route to go public on the market's first trading day of 2016. Its stock jumped on its first day of trading on Monday. An East ...

BioTime will report earnings from Q4 on March 7. Analysts predict BioTime will release losses per share of $0.043. Go here to track BioTime stock price in real-time on Markets Insider. BioTime ...

BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received approximately ...

When a U.S. soldier is wounded in combat, his lost blood is often replaced with Hextend®, a plasma expander developed by BioTime (www.biotimeinc.com). The high molecular weight plasma expander also is ...

Please provide your email address to receive an email when new articles are posted on . Brian Culley has been appointed as CEO of BioTime, succeeding co-CEOs Adi Mohanty and Michael West, PhD, the ...